CD38 as an immunomodulator in cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD38 is a transmembrane glycoprotein expressed across human tissues, particularly the immune system.
• Historically viewed as a cell activation marker, CD38 is now targeted by successful monoclonal antibodies in multiple myeloma treatment.
• This has spurred investigation into CD38's role in other cancers.

Purpose of the Study:

• To provide a comprehensive review of CD38 biology and function outside the context of multiple myeloma.
• To summarize current research findings on CD38 from diverse study areas.
• To explore CD38's potential therapeutic applications in solid tumors and its role as an immunomodulator.

Main Methods:

• Literature review of current research findings on CD38.
• Analysis of CD38's biological functions and expression patterns.
• Synthesis of data regarding CD38's role in various cancers.

Main Results:

• CD38 exhibits significant biological functions beyond its role as a simple marker.
• Emerging evidence suggests CD38's involvement in the immune response within the tumor microenvironment.
• The review consolidates findings supporting CD38's potential as a therapeutic target in solid tumors.

Conclusions:

• CD38's role extends beyond its established function in multiple myeloma.
• CD38 presents a promising target for immunomodulatory therapies in solid tumors.
• Further research is warranted to fully elucidate and exploit CD38's therapeutic potential in oncology.